PortfoliosLab logoPortfoliosLab logo
BIO vs. CLSK
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

BIO vs. CLSK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bio-Rad Laboratories, Inc. (BIO) and CleanSpark, Inc. (CLSK). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, BIO achieves a 1.48% return, which is significantly lower than CLSK's 65.81% return. Over the past 10 years, BIO has outperformed CLSK with an annualized return of 7.54%, while CLSK has yielded a comparatively lower -5.95% annualized return.


BIO

1D
0.87%
1M
19.58%
YTD
1.48%
6M
-3.93%
1Y
38.47%
3Y*
-5.87%
5Y*
-11.96%
10Y*
7.54%

CLSK

1D
-4.71%
1M
25.13%
YTD
65.81%
6M
11.64%
1Y
76.08%
3Y*
62.37%
5Y*
0.32%
10Y*
-5.95%
*Multi-year figures are annualized to reflect compound growth (CAGR)

BIO vs. CLSK - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
BIO
Bio-Rad Laboratories, Inc.
1.48%-7.77%1.74%-23.21%-44.35%29.61%57.54%59.34%-2.70%30.94%
CLSK
CleanSpark, Inc.
65.81%9.88%-16.50%440.69%-78.57%-67.23%442.99%-73.90%-15.98%-30.29%

Correlation

The correlation between BIO and CLSK is 0.18, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.18

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.27

Correlation (10Y)
Calculated over the trailing 10-year period

0.21

Correlation (All Time)
Calculated using the full available price history since Feb 1, 2016

0.20

Fundamentals

EPS

BIO:

$6.24

CLSK:

-$2.24

PS Ratio

BIO:

3.21

CLSK:

5.07

Total Revenue (TTM)

BIO:

$2.59B

CLSK:

$739.88M

Gross Profit (TTM)

BIO:

$1.34B

CLSK:

$306.93M

EBITDA (TTM)

BIO:

$746.20M

CLSK:

-$103.41M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

BIO vs. CLSK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BIO
BIO Risk / Return Rank: 6868
Overall Rank
BIO Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
BIO Sortino Ratio Rank: 6868
Sortino Ratio Rank
BIO Omega Ratio Rank: 6868
Omega Ratio Rank
BIO Calmar Ratio Rank: 6767
Calmar Ratio Rank
BIO Martin Ratio Rank: 6868
Martin Ratio Rank

CLSK
CLSK Risk / Return Rank: 6666
Overall Rank
CLSK Sharpe Ratio Rank: 6969
Sharpe Ratio Rank
CLSK Sortino Ratio Rank: 7070
Sortino Ratio Rank
CLSK Omega Ratio Rank: 6565
Omega Ratio Rank
CLSK Calmar Ratio Rank: 6565
Calmar Ratio Rank
CLSK Martin Ratio Rank: 6161
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BIO vs. CLSK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bio-Rad Laboratories, Inc. (BIO) and CleanSpark, Inc. (CLSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


BIOCLSKDifference
Sharpe ratioReturn per unit of total volatility

+0.08

Sortino ratioReturn per unit of downside risk

-0.04

Omega ratioGain probability vs. loss probability

1.22

1.19

+0.02

Calmar ratioReturn relative to maximum drawdown

1.34

1.18

+0.16

Martin ratioReturn relative to average drawdown

3.21

1.97

+1.24

BIO vs. CLSK - Sharpe Ratio Comparison

The current BIO Sharpe Ratio is 0.94, which is comparable to the CLSK Sharpe Ratio of 0.87. The chart below compares the historical Sharpe Ratios of BIO and CLSK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


BIOCLSKDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.94

0.87

+0.08

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.32

0.00

-0.33

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.22

-0.03

+0.26

Sharpe Ratio (All Time)

Calculated using the full available price history

0.27

-0.03

+0.30

Drawdowns

BIO vs. CLSK - Drawdown Comparison

The maximum BIO drawdown since its inception was -83.64%, smaller than the maximum CLSK drawdown of -98.56%. Use the drawdown chart below to compare losses from any high point for BIO and CLSK.


Loading charts...

Drawdown Indicators


BIOCLSKDifference

Max Drawdown

Largest peak-to-trough decline

-83.64%

-98.56%

+14.92%

Max Drawdown (1Y)

Largest decline over 1 year

-28.86%

-64.74%

+35.88%

Max Drawdown (3Y)

Largest decline over 3 years

-48.76%

-71.28%

+22.52%

Max Drawdown (5Y)

Largest decline over 5 years

-73.77%

-92.00%

+18.23%

Max Drawdown (10Y)

Largest decline over 10 years

-73.77%

-98.56%

+24.79%

Current Drawdown

Current decline from peak

-62.77%

-77.01%

+14.24%

Average Drawdown

Average peak-to-trough decline

-27.73%

-69.49%

+41.76%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.01%

38.67%

-26.66%

Volatility

BIO vs. CLSK - Volatility Comparison

The current volatility for Bio-Rad Laboratories, Inc. (BIO) is 15.42%, while CleanSpark, Inc. (CLSK) has a volatility of 21.14%. This indicates that BIO experiences smaller price fluctuations and is considered to be less risky than CLSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


BIOCLSKDifference

Volatility (1M)

Calculated over the trailing 1-month period

15.42%

21.14%

-5.72%

Volatility (6M)

Calculated over the trailing 6-month period

28.42%

62.43%

-34.01%

Volatility (1Y)

Calculated over the trailing 1-year period

40.99%

88.30%

-47.31%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

37.27%

100.73%

-63.46%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

34.01%

183.19%

-149.18%

Dividends

BIO vs. CLSK - Dividend Comparison

Neither BIO nor CLSK has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

BIO vs. CLSK - Financials Comparison

This section allows you to compare key financial metrics between Bio-Rad Laboratories, Inc. and CleanSpark, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20222023202420252026
592.10M
136.41M
(BIO) Total Revenue
(CLSK) Total Revenue
Values in USD except per share items

Frequently Asked Questions


BIO and CLSK have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CLSK has higher volatility (21.14%) compared to BIO (15.42%). In terms of maximum drawdown, BIO dropped -83.64% vs CLSK's -98.56%.

BIO currently has the higher Sharpe Ratio (0.94 vs 0.87), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for BIO and CLSK

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer